

AUTHORIZATION GRID UPDATE
Changes in Alterwood Authorization Requirements, effective 9/1/2023

Existing Codes Effective 1/1/2024 that require Prior Authorization:

| CPT/HCPS | Full Description |
|----------|--|
| J0887 | Injection, epoetin beta, 1 mcg, (for ESRD on dialysis) |
| J0897 | Injection, denosumab, 1 mg |
| J1569 | Injection, immune globulin, (Gammagard liquid), nonlyophilized, (e.g., liquid), 500 mg |
| J1930 | Injection, lanreotide, 1 mg |
| J2182 | Injection, mepolizumab, 1 mg |
| J2778 | Injection, ranibizumab, 0.1 mg |
| J7327 | Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose |
| J9041 | Injection, bortezomib, 0.1 mg |
| J9227 | Injection, isatuximab-irfc, 10 mg |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-ESRD use) |
| Q0139 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for ESRD on dialysis) |
| Q4081 | Injection, epoetin alfa, 100 units (for ESRD on dialysis) |
| Q5104 | Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg |
| Q5111 | Injection, pegfilgrastim-cbqv (Udenyca), biosimilar, 0.5 mg |
| Q5112 | Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg |
| Q5113 | Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg |
| Q5122 | Injection, pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg |
| Q5123 | Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg |

Existing Codes that NO LONGER require Prior Authorization, effective 1/1/2024:

| CPT/HCPS | Full Description |
|----------|---|
| J0517 | Injection, benralizumab, 1 mg |
| J1300 | Injection, eculizumab, 10 mg |
| J1303 | Injection, ravulizumab-cwvz, 10 mg |
| J1559 | Injection, immune globulin (Hizentra), 100 mg |
| J1561 | Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg |
| J1786 | Injection, imiglucerase, 10 units |
| J2502 | Injection, pasireotide long acting, 1 mg |
| J7201 | Injection, Factor IX, Fc fusion protein, (recombinant), Alprolix, 1 IU |
| J7202 | Injection, Factor IX, albumin fusion protein, (recombinant), Idelvion, 1 IU |
| J7211 | Injection, Factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 IU |
| J7318 | Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg |
| J9294 | Injection, pemetrexed (Hospira), not therapeutically equivalent to J9305, 10 mg |
| J9316 | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |

NEW Codes Effective 1/1/2024 that require Prior Authorization:

| CPT/HCPS | Full Description |
|----------|---|
| 0019M | Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations |
| 0402U | Infectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected |
| 0403U | Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer |
| 0404U | Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression |
| 0405U | Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected |
| 0406U | Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer |
| 0407U | Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function |
| 0408U | Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) |
| 0409U | Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability |
| 0410U | Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected |
| 0411U | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 |
| 0412U | Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology |
| 0413U | Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations |
| 0414U | Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker |
| 0415U | Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS |

NEW Codes Effective 1/1/2024 that require Prior Authorization (continued):

| CPT/HCPS | Full Description |
|----------|---|
| 0416U | Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine |
| 0417U | Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants |
| 0418U | Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score |
| 0419U | Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype |
| A2022 | InnovaBurn or InnovaMatrix XL, per sq cm |
| A2023 | InnovaMatrix PD, 1 mg |
| A2024 | Resolve Matrix, per sq cm |
| A2025 | Miro3D, per cu cm |
| A9156 | Oral mucoadhesive, any type (liquid, gel, paste, etc.), per 1 ml |
| A9292 | Prescription digital visual therapy, software-only, FDA cleared, per course of treatment |
| A9573 | Injection, gadopichlenol, 1 ml |
| A9603 | Injection, pafolacianine, 0.1 mg |
| A9697 | Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose |
| B4148 | Enteral feeding supply kit; elastomeric control fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape |
| C9155 | Injection, epcoritamab-bysp, 0.16 mg |
| C9156 | Flotufolastat F-18, diagnostic, 1 mCi |
| C9157 | Injection, tofersen, 1 mg |
| C9788 | Opto-acoustic imaging, breast (including axilla when performed), unilateral, with image documentation, analysis and report, obtained with ultrasound examination |
| C9789 | Instillation of antineoplastic pharmacologic/biologic agent into renal pelvis, any method, including all imaging guidance, including volumetric measurement if performed |
| C9790 | Histotripsy (i.e., nonthermal ablation via acoustic energy delivery) of malignant renal tissue, including image guidance |
| C9791 | Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent |

NEW Codes Effective 1/1/2024 that require Prior Authorization (continued):

| CPT/HCPS | Full Description |
|----------|--|
| C9792 | Blinded or nonblinded procedure for symptomatic New York Heart Association (NYHA) Class II, III, IVA heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (e.g., transesophageal echocardiography (TTE), intracardiac echocardiography (ICE), fluoroscopy), performed under general anesthesia in an approved investigational device exemption (IDE) study |
| E0490 | Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote |
| E0491 | Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply |
| J0174 | Injection, lecanemab-irmb, 1 mg |
| J0801 | Injection, corticotropin (Acthar Gel), up to 40 units |
| J0802 | Injection, corticotropin (ANI), up to 40 units |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg |
| J7214 | Injection, Factor VIII/von Willebrand factor complex, recombinant (Altuviiiio), per Factor VIII IU |
| J9064 | Injection, cabazitaxel (Sandoz), not therapeutically equivalent to J9043, 1 mg |
| J9345 | Injection, retifanlimab-dlwr, 1 mg |
| L1681 | Hip orthosis (HO), bilateral hip joints and thigh cuffs, adjustable flexion, extension, abduction control of hip joint, postoperative hip abduction type, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
| L5991 | Addition to lower extremity prostheses, osseointegrated external prosthetic connector |
| Q4285 | NuDYN DL or NuDYN DL MESH, per sq cm |
| Q4286 | NuDYN SL or NuDYN SLW, per sq cm |

NEW Codes Effective 1/1/2024 that DO NOT require Prior Authorization:

| CPT/HCPS | Full Description |
|----------|---|
| 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use |
| 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use |
| 90480 | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose |
| 91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use |
| 91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use |
| 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| 91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
| 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
| C9152 | Injection, aripiprazole, (Abilify Asimtufii), 1 mg |
| C9153 | Injection, amisulpride, 1 mg |
| C9154 | Injection, buprenorphine extended-release (Brixadi), 1 mg |
| C9158 | Injection, risperidone, (Uzedy), 1 mg |
| J0349 | Injection, rezafungin, 1 mg |
| J0874 | Injection, daptomycin (Baxter), not therapeutically equivalent to J0878, 1 mg |
| J2359 | Injection, olanzapine, 0.5 mg |
| J7353 | Anacaulase-bcdb, 8.8% gel, 1 gm |
| J7519 | Injection, mycophenolate mofetil, 10 mg |
| J9051 | Injection, bortezomib (MAIA), not therapeutically equivalent to J9041, 0.1 mg |

NEW Codes Effective 1/1/2024 that are NOT COVERED by Medicare/Alterwood:

| CPT/HCPS | Full Description |
|----------|--|
| A9268 | Programmer for transient, orally ingested capsule |
| A9269 | Programmable, transient, orally ingested capsule, for use with external programmer, per month |
| H2040 | Coordinated specialty care, team-based, for first episode psychosis, per month |
| H2041 | Coordinated specialty care, team-based, for first episode psychosis, per encounter |
| K1036 | Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month |
| V2526 | Contact lens, hydrophilic, with blue-violet filter, per lens |